Compounding Knowledge: Fighting Insanitary Conditions Before They Start - April 2026
Includes a Live Web Event on 04/08/2026 at 12:00 PM (EDT)
Recorded On: 04/08/2026
-
Register
- Prices available after logging in
FDA insanitary conditions are important to discuss in both the 503A and 503B spaces. This session examines the most common findings, including microbial contamination risks, poor facility design, and inadequate personnel practices. Attendees will learn how to proactively identify and remediate potential insanitary conditions before they result in regulatory action.
- Identify the most common insanitary conditions cited by FDA in 503A and 503B compounding settings.
- Explain how facility design, personnel behaviors, and environmental risks contribute to microbial contamination.
- Implement proactive strategies to detect, prevent, and remediate insanitary conditions before they result in regulatory action.
Barbara Petroff, MS, RPh, FASHP, BCSCP, FNHIA, CAC, CSPP, IgCP
Principal
Shawler Petroff LLC
Barbara Petroff is a graduate of Ohio State University College of Pharmacy. She completed a Master's Degree in Administration at Central Michigan University. After starting her career in research in Product Development specializing in sterile products she worked for several years in hospital pharmacy before turning to home infusion where she has been for over 30 years. In addition she was a surveyor for the ACHC for 23 years, taught Healthcare Management at University of Phoenix, was adjunct faculty for five schools of pharmacy and currently teaches a pharmacy technician training class. She has been a member of ASHP for many years serving on several committees. She was on the Executive Committee for the Section of Ambulatory Care Practitioners and served as the Chair of the Home Infusion Section Advisory Group. She has been a member of NHIA and currently serves as the chair of the Sterile Compounding Practice Committee.
NHIA Requires planners, faculty, and others who affect the content of this activity to disclose all financial relationships they have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to policy.
Barbara Petroff has no relevant financial relationships with ineligible companies to disclose.
